Lance's Corner

FDA Issues Guidance on Pulse Oximeters

Mar 26, 2025

Per the notice below, the United States Food and Drug Administration (FDA) has issued guidance on the basics of using pulse oximeters.

Pulse Oximeter Basics

A pulse oximeter, or pulse ox, is a device that estimates the amount of oxygen in the blood.  Here’s what to know before using one.

We need oxygen to survive.  Sometimes the amount of oxygen in the blood falls too low for the body to function well.  Asthma, lung cancer, chronic obstructive pulmonary disease, the flu, and heart disease are among the health conditions that can cause oxygen levels to drop.  Being at higher altitudes, where the amount of oxygen in the air can be less than at sea level, can be another factor that can cause oxygen levels to drop.  One way to monitor the level of oxygen in the blood is by using a device called a pulse oximeter, or pulse ox.  A pulse oximeter can estimate the amount of oxygen in the blood without having to draw a blood sample.

What is a pulse oximeter?

A pulse oximeter is a device that is usually clipped on a fingertip and uses light beams to estimate a person’s blood oxygen level (oxygen saturation) and their pulse rate.  Most pulse oximeters show two or three numbers.  The most important number, oxygen saturation level, is usually abbreviated SpO2, and is presented as a percentage.  The pulse rate (similar to heart rate) is typically abbreviated PR.  Sometimes there is a third number for strength of the signal.  Oxygen saturation values are between 95% and 100% for most healthy individuals but sometimes can be lower in people with lung and heart problems, for example.  Oxygen saturation levels are also generally slightly lower for those living at higher altitudes.

Using a pulse oximeter

If you are using a pulse oximeter to monitor your oxygen levels at home, in addition to your pulse oximeter reading, keep track of your symptoms and how you feel.  Contact a health care provider if you are concerned about the pulse oximeter reading, or your symptoms are serious or get worse.  To get the best reading when using a pulse oximeter at home:

  • Follow your health care provider’s advice about when and how often to check your oxygen levels.
  • Follow the manufacturer’s instructions for use.
  • When placing the pulse oximeter on your finger, make sure your hand is warm, relaxed, and held below the level of the heart.  Remove any fingernail polish on that finger.
  • Sit still and do not move the part of your body where the pulse oximeter is located.
  • Wait a few seconds until the reading stops changing and displays one steady number.
  • Write down your oxygen level and the date and time of the reading so you can track any changes and report these to your health care provider.

Be familiar with signs or symptoms of low oxygen levels:

  • Bluish coloring in the face, lips, or nails.
  • Shortness of breath, difficulty breathing, or a cough that gets worse.
  • Restlessness and discomfort.
  • Chest pain or tightness.
  • Fast/racing pulse rate.

Be aware that some people with low oxygen levels may not show any or all these symptoms.  Only a health care provider can diagnose a medical condition such as hypoxia (low oxygen levels).  Pulse oximeter readings should be considered in context with other information, including signs and symptoms of low oxygen.  As with any device, there is always a risk of an inaccurate reading.  Be aware multiple factors can affect the accuracy of a pulse oximeter reading, such as poor circulation, skin pigmentation, skin thickness, skin temperature, current tobacco use, and use of fingernail polish.

Categories of pulse oximeters and FDA clearance

Certain pulse oximeters are intended for medical purposes and are primarily used in hospital settings or doctors’ offices.  Pulse oximeters for medical purposes are typically used to monitor (i.e. trending or spot checking) oxygen saturation levels of patients to help in clinical decision-making.  Currently, a small number of these pulse oximeters intended for medical purposes are available over the counter (OTC) following clearance by the FDA.  There also are pulse oximeters that are sold as general wellness products or sporting/aviation products.  These are not reviewed or evaluated by the agency before being available to the public.  Such products are often sold directly to consumers in stores or online and are intended for estimating oxygen saturation often for purposes of general wellness (such as encouraging a general state of health or healthy lifestyle).  The FDA recognizes that during the COVID-19 pandemic, many people purchased OTC pulse oximeters that are considered general wellness products.  These products are not evaluated by the agency for use in clinical decision-making or determining whether to seek medical intervention.  Current scientific evidence suggests there are some accuracy differences in pulse oximeter performance between individuals with lighter and darker skin pigmentation.  The FDA previously informed patients and health care professionals that although pulse oximetry is useful for estimating blood oxygen levels, pulse oximeters have limitations and a risk of inaccuracy under certain circumstances, including use on patients with darker skin pigmentation, that should be considered.  In addition to the safety communication, to address concerns around the accuracy of these devices, the FDA held advisory committee meetings, published a discussion paper for comment, and published a draft guidance in January 2025 that outlines proposed recommendations to help improve the accuracy and performance of pulse oximeters that are used for medical purposes across the range of skin pigmentations.

Reporting Problems with a Device

If you experienced a problem or injury that you think may be related to a pulse oximeter, you can voluntarily report it through the FDA’s MedWatch program.

USDOL Issues Comprehensive Employer Guidance on Long COVID

The United States Department of Labor (USDOL) has issued a comprehensive set of resources that can be accessed below for employers on dealing with Long COVID.

Supporting Employees with Long COVID: A Guide for Employers

The “Supporting Employees with Long COVID” guide from the USDOL-funded Employer Assistance and Resource Network on Disability Inclusion (EARN) and Job Accommodation Network (JAN) addresses the basics of Long COVID, including its intersection with mental health, and common workplace supports for different symptoms.  It also explores employers’ responsibilities to provide reasonable accommodations and answers frequently asked questions about Long COVID and employment, including inquiries related to telework and leave.

Download the guide

Accommodation and Compliance: Long COVID

The Long COVID Accommodation and Compliance webpage from the USDOL-funded Job Accommodation Network (JAN) helps employers and employees understand strategies for supporting workers with Long COVID.  Topics include Long COVID in the context of disability under the Americans with Disabilities Act (ADA), specific accommodation ideas based on limitations or work-related functions, common situations and solutions, and questions to consider when identifying effective accommodations for employees with Long COVID.  Find this and other Long COVID resources from JAN, below:

Long COVID, Disability and Underserved Communities: Recommendations for Employers

The research-to-practice brief “Long COVID, Disability and Underserved Communities” synthesizes an extensive review of documents, literature and data sources, conducted by the USDOL-funded Employer Assistance and Resource Network on Disability Inclusion (EARN) on the impact of Long COVID on employment, with a focus on demographic differences.  It also outlines recommended actions organizations can take to create a supportive and inclusive workplace culture for people with Long COVID, especially those with disabilities who belong to other historically underserved groups.

Read the brief

Long COVID and Disability Accommodations in the Workplace

The policy brief “Long COVID and Disability Accommodations in the Workplace” explores Long COVID’s impact on the workforce and provides examples of policy actions different states are taking to help affected people remain at work or return when ready.  It was developed by the National Conference of State Legislatures (NCSL) as part of its involvement in USDOL’s State Exchange on Employment and Disability (SEED) initiative.

Download the policy brief

Understanding and Addressing the Workplace Challenges Related to Long COVID

The report “Understanding and Addressing the Workplace Challenges Related to Long COVID” summarizes key themes and takeaways from an ePolicyWorks national online dialogue through which members of the public were invited to share their experiences and insights regarding workplace challenges posed by Long COVID.  The dialogue took place during summer 2022 and was hosted by USDOL and its agencies in collaboration with the Centers for Disease Control and Prevention and the U.S. Surgeon General.

Download the report

Working with Long COVID

The USDOL-published “Working with Long COVID” fact sheet shares strategies for supporting workers with Long COVID, including accommodations for common symptoms and resources for further guidance and assistance with specific situations.

Download the fact sheet

COVID-19: Long-Term Symptoms

This USDOL motion graphic informs workers with Long COVID that they may be entitled to temporary or long-term supports to help them stay on the job or return to work when ready, and shares where they can find related assistance.

Watch the motion graphic

A Personal Story of Long COVID and Disability Disclosure

In the podcast “A Personal Story of Long COVID and Disability Disclosure,” Pam Bingham, senior program manager for Intuit’s Diversity, Equity and Inclusion in Tech team, shares her personal experience of navigating Long COVID symptoms at work.  The segment was produced by the USDOL-funded Partnership on Employment and Accessible Technology (PEAT) as part of its ongoing “Future of Work” podcast series.

Listen to the podcast

HHS OIG Issues Annual Report on State MFCUs

Per the notice below, the Office of the Inspector General (OIG) of the United States Department of Health and Human Services (HHS) has issued its annual report on the performance of state Medicaid Fraud Control Units (MFCUs).

Medicaid Fraud Control Units Fiscal Year 2023 Annual Report (OEI-09-24-00200) 

Medicaid Fraud Control Units (MFCUs) investigate and prosecute Medicaid provider fraud and patient abuse or neglect. OIG is the Federal agency that oversees and annually approves federal funding for MFCUs through a recertification process. This new report analyzed the statistical data on annual case outcomes—such as convictions, civil settlements and judgments, and recoveries—that the 53 MFCUs submitted for Fiscal Year 2023.  New York data is as follows:

Outcomes

  • Investigations1 - 556
  • Indicted/Charged - 9
  • Convictions - 8
  • Civil Settlements/Judgments - 28
  • Recoveries2 - $73,204,518

Resources

  • MFCU Expenditures3 - $55,964,293
  • Staff on Board4 - 257

1Investigations are defined as the total number of open investigations at the end of the fiscal year.

2Recoveries are defined as the amount of money that defendants are required to pay as a result of a settlement, judgment, or prefiling settlement in criminal and civil cases and may not reflect actual collections.  Recoveries may involve cases that include participation by other Federal and State agencies.

3MFCU and Medicaid Expenditures include both State and Federal expenditures.

4Staff on Board is defined as the total number of staff employed by the Unit at the end of the fiscal year.

Read the Full Report

View the Statistical Chart

Engage with the Interactive Map

GAO Issues Report on Medicaid Managed Care Service Denials and Appeal Outcomes

The United States Government Accountability Office (GAO) has issued a report on federal use of state data on Medicaid managed care service denials and appeal outcomes.  GAO found that federal oversight is limited because it doesn't require states to report on Medicaid managed care service denials or appeal outcomes and there has not been much progress on plans to analyze and make the data publicly available.  To read the GAO report on federal use of state data on Medicaid managed care service denials and appeal outcomes, use the first link below.  To read GAO highlights of the report on federal use of state data on Medicaid managed care service denials and appeal outcomes, use the second link below.
https://www.gao.gov/assets/d24106627.pdf  (GAO report on federal use of state data on Medicaid managed care service denials and appeal outcomes)
https://www.gao.gov/assets/d24106627_high.pdf  (GAO highlights on federal use of state data on Medicaid managed care service denials and appeal outcomes)

CMS Issues Latest Medicare Regulatory Activities Update

The Centers for Medicare and Medicaid Services (CMS) has issued its latest update on its regulatory activities in the Medicare program.  While dentistry is only minimally connected to the Medicare program, Medicare drives the majority of health care policies and insurance reimbursement policies throughout the country.  Therefore, it always pays to keep a close eye on what CMS is doing in Medicare.  To read the latest CMS update on its regulatory activities in Medicare, use the link below.
https://www.cms.gov/training-education/medicare-learning-network/newsletter/2024-03-14-mlnc